Growth stocks can be some of the most exciting picks in the market, as these high-flyers can captivate investors’ attention, and produce big gains as well. However, they can also lead on the downside when the growth story is over, so it is important to find companies which are still seeing strong growth prospects in their businesses.
One such company that might be well-positioned for future earnings growth is Bio-Rad Laboratories, Inc. BIO. This firm, which is in the Medical - Products, saw EPS growth of 42.4% last year, and is looking great for this year too.
In fact, the current growth estimate for this year calls for earnings-per-share growth of 22.6%. Furthermore, the long-term growth rate is currently an impressive 15%, suggesting pretty good prospects for the long haul.
Bio-Rad Laboratories, Inc. Price and Consensus
Bio-Rad Laboratories, Inc. Price and Consensus | Bio-Rad Laboratories, Inc. Quote
And if this wasn’t enough, the stock has actually seen estimates rise over the past month for the current fiscal year by about 5.6%. Thanks to this rise in earnings estimates, BIO has a Zacks Rank #1 (Strong Buy) which further underscores the potential for outperformance in this company. You can see the complete list of today’s Zacks #1 Rank stocks here.
So, if you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider BIO. Not only does it have double-digit earnings growth prospects, but its impressive Zacks Rank suggests that analysts believe better days are ahead for BIO as well.
Is Your Investment Advisor Fumbling Your Financial Future?
See how you can more effectively safeguard your retirement with a new Special Report, “4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future.”
Click to get it free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bio-Rad Laboratories, Inc. (BIO) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research